Picard Medical Reports Third Quarter 2026 Financial Results; Gross Profit Positive for Third Consecutive Quarter; Net Loss Narrows 79% to $2.2 Million
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Picard Medical (NYSE American: PMI) narrowed its third-quarter 2026 net loss to $2.2 million, recording its third consecutive quarter of positive gross profit. Revenue fell to approximately $0.2 million from approximately $1.2 million a year earlier, while operating expenses decreased 35%. Nine-month revenue rose 10% to approximately $4.3 million, and net loss narrowed to $15.5 million from approximately $22.7 million.
Cash was approximately $67,000 at September 30. The company needs additional financing and identified substantial doubt about continuing as a going concern. Its Senior Secured Note was fully repaid and settled. Picard expects fourth-quarter net product sales to exceed approximately $900,000 a year earlier. Emperor artificial-heart drive-system testing exceeded 18 million operating cycles. Continued listing remains subject to compliance-plan milestones and quarterly review.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThird-quarter net loss narrowed 79% to $2.2 million from $10.4 million a year earlier.
- Moderate pointNine-month revenue increased 10% to approximately $4.3 million from $3.9 million in the prior-year period.
- Moderate pointNine-month gross profit reached $1.0 million, reversing an approximately $0.6 million prior-year gross loss.
- Moderate pointSenior Secured Note repayment and settlement completed, with no principal outstanding at September 30, 2026.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Fourth-quarter 2026 net product sales are expected to exceed approximately $900,000 in fourth-quarter 2025, based on preliminary results and confirmed orders.
11 minor points
- Minor pointThird-quarter gross profit of $0.1 million reversed an approximately $0.1 million year-earlier gross loss.
- Minor pointThird-quarter operating expenses decreased 35% to $2.2 million from $3.4 million a year earlier.
- Minor pointThird-quarter operating loss improved 40% to approximately $2.1 million from approximately $3.5 million a year earlier.
- Minor pointThird-quarter cost of revenue decreased approximately $1.2 million, or 91%, versus the prior-year period.
- Minor pointNine-month rental revenue increased to approximately $0.4 million from $0.1 million in the prior-year period.
- Minor pointNine-month gross margin improved to approximately 22.8% from negative 15.6% in the prior-year period.
- Minor pointNine-month net loss narrowed to $15.5 million from approximately $22.7 million, despite debt-settlement and warrant-exchange losses.
- Minor point. Forward-looking: it has not happened yet and may not happen.C2 Hospital Driver rental pricing is being developed to add a hospital-based rental revenue stream.
- Minor pointEmperor drive-system reliability testing exceeded 18 million operating cycles during ongoing preclinical and engineering development.
- Minor point. Forward-looking: it has not happened yet and may not happen.Next-generation pneumatic driver development continues, targeting lower costs, better supply availability and broader adoption.
- Minor pointNIH/NHLBI grant of up to $606,498 supports Emperor development from September 1, 2026, through August 31, 2027.
Negative
- Major pointCash was approximately $67,000 at September 30, 2026; additional financing is needed amid going-concern doubt.
- Moderate pointNYSE American continued listing is conditional on compliance-plan milestones and ongoing quarterly review.
- Moderate pointThird-quarter revenue fell to approximately $0.2 million from approximately $1.2 million a year earlier.
- Moderate pointNine-month operating expenses increased to approximately $12.2 million from approximately $9.6 million in the prior-year period.
- Moderate pointNine-month operating loss widened to approximately $11.2 million from approximately $10.3 million in the prior-year period.
2 minor points
- Minor pointThird-quarter product sales revenue was zero, versus approximately $1.1 million a year earlier; Picard cited patient scheduling.
- Minor point. Forward-looking: it has not happened yet and may not happen.C2 rental revenue contribution depends on pricing implementation, customer adoption and actual utilization.
News Explained
The NIH grant’s ceiling is not cash received: the release reports up to $606,498 authorized and approximately $200,000 recognized as income.
Picard Medical reported third-quarter 2026 results and said it will need additional capital to fund operations; at September 30, it had
The NIH/NHLBI SBIR award was for up to
Picard is updating its commercial pricing model to add a rental component for hospital drivers, but says the timing and financial contribution depend on implementation, customer adoption and actual utilization.
Sources and calculations
- Picard Medical third-quarter 2026 results release (2026-11-16)
- Picard Medical third-quarter 2026 financial fundamentals (2026Q3)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $67,000 / ($1,996,000 / 92) = 3.1 days
Key Figures
- Q3 revenue
- Approximately $0.2 million vs. approximately $1.2 million
- Third quarter 2026 vs. same quarter last year
- Q3 gross profit
- $0.1 million vs. a gross loss of approximately $0.1 million
- Third quarter 2026 vs. same quarter last year
- Operating expenses
- $2.2 million, down 35% from $3.4 million
- Third quarter 2026 vs. same quarter last year
- Net loss
- $2.2 million, down 79% from $10.4 million
- Third quarter 2026 vs. same quarter last year
- Nine-month revenue
- Approximately $4.3 million, up 10% from $3.9 million
- Nine months ended September 30, 2026 vs. prior-year period
- Nine-month gross profit
- $1.0 million vs. a gross loss of approximately $0.6 million
- Nine months ended September 30, 2026 vs. prior-year period
- Expected Q4 net product sales
- Expected to exceed approximately $900,000
- Fourth quarter 2026 vs. reported fourth quarter 2025; based on preliminary results and confirmed orders as of November 12, 2026
- Cash and cash equivalents
- $0.1 million
- As of September 30, 2026; the company disclosed a need for additional capital and substantial doubt about its ability to continue as a going concern
Previous Earnings Reports
-
Q2 revenue rose 39%, gross profit turned positive, and net loss narrowed 16%.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
total artificial heart medical
preclinical medical
small business innovation research financial
going concern financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Year to Date Gross Profit Compared with Gross Loss in Prior-Year Period; Nine-Month Net Loss Decreases
Emperor Total Artificial Heart Development Advances, with Drive-System Testing Exceeding 18 Million Operating Cycles
TUCSON, Ariz., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC (“SynCardia”), maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today reported financial results for the third quarter ended September 30, 2026.
For the third quarter of 2026, the Company reported positive gross profit for the third consecutive quarter, reduced operating expenses by
The Company continued development of its next-generation Emperor Total Artificial Heart (“Emperor TAH”) platform during the third quarter, including motor and control-system development, design optimization and bench testing. Early reliability testing of the Emperor drive system has now exceeded 18 million operating cycles.
“Our third-quarter results show a business that is becoming structurally stronger,” said Richard Fang, Executive Chairman and Chief Executive Officer of Picard Medical. “We delivered our third consecutive quarter of positive gross profit, reduced operating expenses by
“At the same time, we continue to invest in the future of the therapy,” Fang continued. “The Emperor drive system has now surpassed 18 million operating cycles in reliability testing, we presented the platform’s integrated architecture to the biomedical engineering community at IEEE EMBC 2026, and the NIH/NHLBI SBIR award reflects external recognition of the program’s potential. Our goal is to give more patients with end-stage heart failure a durable path to transplant and, ultimately, a fully implantable alternative.”
Third Quarter 2026 Financial Highlights
- Total revenue was approximately
$0.2 million compared with approximately$1.2 million in the same quarter last year. - Gross profit was
$0.1 million compared with a gross loss of approximately$0.1 million in the same quarter last year. - Operating expenses decreased
35% to$2.2 million compared with$3.4 million in the same quarter last year. - Operating loss improved
40% to approximately$2.1 million compared with approximately$3.5 million in the same quarter last year. - Net loss was
$2.2 million compared with$10.4 million in the same quarter last year.
Nine Months Ended September 30, 2026, Financial Highlights
- Total revenue increased
10% to approximately$4.3 million compared to$3.9 million in the prior year period. - Product revenue was approximately
$3.9 million . - Rental revenue increased to approximately
$0.4 million compared to$0.1 million in the prior year period. - Gross profit improved to
$1.0 million compared with a gross loss of approximately$0.6 million in the prior year period. - Gross margin improved to approximately
22.8% 9 compared with negative15.6% in the prior year period. - Operating expenses increased to approximately
$12.2 million compared with approximately$9.6 million in the prior year period, primarily reflecting higher research and development and selling, general and administrative expenses. - Operating loss was approximately
$11.2 million compared with approximately$10.3 million in the prior year period. - Net loss decreased to
$15.5 million compared with approximately$22.7 million in the prior year period. The improvement primarily reflects lower interest and derivative-related expenses and changes in the fair value of financial liabilities, partially offset by losses associated with debt settlement and warrant exchange. - Balance sheet as of September 30, 2026, the Company had cash and cash equivalents of
$0.1 million and stockholders’ equity of$1.3 million . The Company will need to raise additional capital to fund operations, and its Quarterly Report on Form 10-Q includes disclosure regarding substantial doubt about its ability to continue as a going concern.
Business and Strategic Highlights
Commercial Operations and Revenue Model Expansion
The Company generates revenue through the sale of SynCardia Total Artificial Heart systems, rental of Freedom Drivers for patients discharged from the hospital, and training and certification services required before a transplant center's initial deployment of a SynCardia TAH. These products and services support hospital and transplant center customers in the United States and internationally.
In addition to its existing revenue streams, the Company is updating its commercial pricing model to incorporate rental revenue from its Companion 2 (“C2”) Hospital Drivers, which provide pneumatic support for patients while receiving treatment in the hospital. This initiative is intended to expand the Company's revenue opportunities by establishing a rental component for hospital-based driver utilization, in addition to existing TAH product sales, Freedom Driver rentals and training and certification services.
The Company believes that expanding its rental-based revenue model can create additional revenue opportunities across its installed hospital customer base and complement future growth in TAH product sales. The timing and financial contribution of this initiative will depend on the implementation of the updated pricing model, customer adoption, and actual utilization.
SynCardia Commercial Operations and Manufacturing
During the third quarter, the Company continued initiatives to improve manufacturing efficiency and cost management. These efforts include transitioning selected manufacturing activities in-house, utilizing existing personnel and facilities more efficiently, improving finished goods inventory management and onboarding more cost-effective suppliers.
These initiatives contributed to a reduction of approximately
The Company continues to focus on supporting hospital customers, improving operational execution, and positioning its manufacturing capabilities to support future commercial requirements.
Emperor Total Artificial Heart Development
The Company continued preclinical and engineering development of the Emperor TAH platform during the third quarter. Development activities included motor and control-system development, design optimization and bench testing.
Early reliability testing of the Emperor drive system has exceeded 18 million operating cycles to date.
In July 2026, the Company publicly presented the integrated architecture of the Emperor TAH platform at the 48th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (“IEEE EMBC 2026”). The presentation provided the biomedical engineering community with a detailed view of the platform and its electromechanical drive architecture.
The Company also continues development of a next-generation pneumatic driver for the SynCardia TAH, with the objectives of reducing costs, improving supply availability and supporting broader adoption.
NIH/NHLBI Research Grant
In August 2026, the National Institutes of Health’s National Heart, Lung, and Blood Institute (“NIH/NHLBI”) awarded SynCardia Systems, LLC a Small Business Innovation Research (“SBIR”) grant of up to
The project and budget periods extend from September 1, 2026, through August 31, 2027. The Company recognized approximately
Commercial Outlook
During the third quarter, the Company did not recognize product sales revenue, compared with approximately
Based on preliminary results and confirmed orders as of November 12, 2026, the Company expects net product sales for the fourth quarter of 2026 to exceed the approximately
The Company believes that anticipated product sales, together with continued growth in rental revenue and the planned expansion of its hospital driver rental pricing model, represent opportunities to broaden its commercial revenue base.
Corporate and Financial Update
During the nine months ended September 30, 2026, the Company completed the repayment and settlement of its Senior Secured Note, with no principal remaining outstanding as of September 30, 2026. The Company believes this represents an important milestone in its efforts to address its capital structure.
As of September 30, 2026, the Company reported approximately
In July 2026, NYSE American accepted the Company’s plan of compliance, allowing the Company to continue its listing subject to achievement of the plan’s milestones and ongoing quarterly review. The Company remains focused on satisfying the applicable listing requirements.
As of November 12, 2026, the Company had 2,661,574 shares of common stock outstanding.
Looking Ahead
“We are clear-eyed about our capital needs and the work that remains,” Fang said. “Our priorities are straightforward: return product sales to growth, build recurring rental revenue across our hospital customer base, strengthen our balance sheet, satisfy NYSE American continued listing standards and advance Emperor toward clinical readiness. We believe disciplined execution against these priorities is the path to long-term value for patients and stockholders.”
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona-based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the U.S. Food and Drug Administration and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”) at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on management’s current expectations, assumptions and beliefs and involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. These statements may be identified by words such as “anticipate,” “believe,” “continue,” “expect,” “intend,” “may,” “plan,” “potential,” “will” and similar expressions, or the negatives of these terms.
Forward-looking statements in this press release include, but are not limited to, statements regarding the Company’s expectations for fourth-quarter 2026 product sales; anticipated customer orders and delivery schedules; the implementation and potential financial contribution of the updated C2 Hospital Driver rental pricing model; continued development, testing and potential commercialization of the Emperor TAH platform and next-generation pneumatic driver; manufacturing initiatives and expected operational efficiencies; the Company’s ability to improve revenue, gross profitability and operating performance; the use of grant funding; the Company’s ability to obtain additional financing and fund ongoing operations; and the Company’s ability to satisfy NYSE American listing requirements.
These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include, among others, changes in hospital customer needs and patient schedules, delays or changes in product orders and delivery schedules, the Company’s ability to execute its manufacturing and development plans, customer adoption of the updated rental pricing model, the availability of additional financing on acceptable terms, regulatory and clinical development risks, and the other risks described in the Company’s filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances after the date of this release, except as required by law.
Contact
Picard Medical, Inc. / SynCardia Systems, LLC IR@picardmedical.com
Melissa Morales - Office Manager | Executive Assistant - mmorales@syncardia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Picard Medical's third-quarter 2026 earnings results?
Picard Medical reported a $2.2 million net loss, compared with $10.4 million a year earlier. Revenue was approximately $0.2 million versus approximately $1.2 million. Gross profit was $0.1 million, marking the third consecutive quarter of positive gross profit.
What does Picard Medical expect for fourth-quarter 2026 product sales?
Picard expects fourth-quarter 2026 net product sales to exceed approximately $900,000 reported in fourth-quarter 2025. The outlook is based on preliminary results and confirmed orders as of November 12, 2026, primarily for SynCardia Total Artificial Hearts. Actual results may differ with customer delivery schedules.
How much income has Picard Medical recognized from the Emperor NIH grant?
Picard recognized approximately $200,000 in grant-related other income as of November 12, 2026. Approximately $100,000 was recognized during the third quarter and first nine months of 2026. The grant authorizes up to $606,498; that maximum is not the amount of income recognized or cash received.